1
|
Davis PM, Ravkov E, de Geus M, Clauss Z, Lee J, Nguyen AT, Hartmann M, Kim J, George TI, Lin L, Ng DP. Synthetic abnormal mast cell particles successfully mimic neoplastic mast cells by flow cytometry. CYTOMETRY. PART B, CLINICAL CYTOMETRY 2024. [PMID: 38816961 DOI: 10.1002/cyto.b.22183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/05/2024] [Revised: 04/12/2024] [Accepted: 05/15/2024] [Indexed: 06/01/2024]
Abstract
Clinical flow cytometry laboratories require quality control materials for assay development, validation, and performance monitoring, including new reagent lot qualification. However, finding suitable controls for populations with uncommonly expressed antigens or for rare populations, such as mast cells, can be difficult. To that end, we evaluated synthetic abnormal mast cell particles (SAMCP), developed together with, and manufactured by, Slingshot Biosciences. The SAMCP's were designed to phenotypically mimic abnormal neoplastic mast cells: they were customized to have the same light scatter and autofluorescence properties of mast cells, along with surface antigen levels of CD45, CD33, CD117, CD2, CD25, and CD30 consistent with that seen in mast cell disease. We evaluated several performance characteristics of these particles using ARUP's high sensitivity clinical mast cell assay, including limit of detection, off-target activity and FMO controls, precision, scatter properties of the particles utilizing several different cytometer platforms, and particle antigen stability. The phenotype of the SAMCP mimicked abnormal mast cells, and they could be distinguished from normal native mast cells. FMO controls demonstrated specificity of each of the markers, and no off-target binding was detected. The limit of detection of the particles spiked into normal bone marrow was found to be ≤0.003% in a limiting dilution assay. The mast cell particles were found to perform similarly on Becton Dickinson Lyric, Cytek Aurora, and Beckman Coulter Navios and CytoFLEX platforms. Within run and between run precision were less than 10% CV. SAMCP were stable up to 13 days with minimal loss of antigen fluorescence intensity. The SAMCP's were able to successfully mimic neoplastic mast cells based on the results of our high sensitivity mast cell flow cytometry panel. These synthetic cell particles represent an exciting and innovative technology, which can fulfill vital needs in clinical flow cytometry such as serving as standardized control materials for assay development and performance monitoring.
Collapse
Affiliation(s)
- Patricia M Davis
- ARUP Institute for Clinical & Experimental Pathology, ARUP Laboratories, Salt Lake City, Utah, USA
| | - Eugene Ravkov
- ARUP Institute for Clinical & Experimental Pathology, ARUP Laboratories, Salt Lake City, Utah, USA
| | | | - Zach Clauss
- Slingshot Biosciences, Emeryville, California, USA
| | - John Lee
- Slingshot Biosciences, Emeryville, California, USA
| | | | | | - Jeffrey Kim
- Slingshot Biosciences, Emeryville, California, USA
| | - Tracy I George
- ARUP Institute for Clinical & Experimental Pathology, ARUP Laboratories, Salt Lake City, Utah, USA
- Department of Pathology, University of Utah, Salt Lake City, Utah, USA
| | - Leo Lin
- ARUP Institute for Clinical & Experimental Pathology, ARUP Laboratories, Salt Lake City, Utah, USA
- Department of Pathology, University of Utah, Salt Lake City, Utah, USA
| | - David P Ng
- ARUP Institute for Clinical & Experimental Pathology, ARUP Laboratories, Salt Lake City, Utah, USA
- Department of Pathology, University of Utah, Salt Lake City, Utah, USA
| |
Collapse
|
2
|
Kappelmayer J. Issue highlights-November 2022. CYTOMETRY. PART B, CLINICAL CYTOMETRY 2022; 102:425-426. [PMID: 36398856 DOI: 10.1002/cyto.b.22101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 11/05/2022] [Indexed: 11/19/2022]
Affiliation(s)
- János Kappelmayer
- Department of Laboratory Medicine, University of Debrecen, Debrecen, Hungary
| |
Collapse
|
3
|
Mulder AHL, Eidhof HHM, Gratama JW. External quality assessment of flow cytometric bronchoalveolar lavage cellular analysis: 20 years' experience in The Netherlands. CYTOMETRY. PART B, CLINICAL CYTOMETRY 2022; 102:451-457. [PMID: 36070226 DOI: 10.1002/cyto.b.22090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/08/2022] [Revised: 07/28/2022] [Accepted: 08/23/2022] [Indexed: 01/31/2023]
Abstract
BACKGROUND Bronchoalveolar (BAL) cellular analysis can be supportive in the diagnosis of interstitial lung disease. The flow cytometric analysis of BAL fluid cells is complicated by cell fragility and adherence and autofluorescence of macrophages, making conventional analysis of BAL fluid cells as done in external quality schemes (EQA) for blood lymphocyte subsets, not representative. Following a procedure for stabilized BAL cells, a separate EQA was set up. The results of 20 years' experience are presented. METHODS From each round between 2000 and 2020 the following flow cytometric parameters were recorded from each participant: total lymphocyte population (TLY), CD3+ lymphocytes, CD3+ CD4+ lymphocytes, CD3+ CD8+ lymphocytes, CD3- CD16+/56+ lymphocytes, CD19+ lymphocytes and CD103 + CD3+ lymphocytes. In addition, the eosinophils and neutrophils were recorded. The mean and standard deviation of each parameter per round were calculated. The 40 rounds were divided in four respective groups of 10 in order to compare the results as function of time. In addition the interpretation of the results of participants was scored. RESULTS The median SD in the four groups was below 10% for all parameters except for TLY and the CD103+ CD3+ lymphocytes. No improvement in time was observed for any (sub)population except for the CD3+ CD4+ subset. Interpretation of the results varied based on disease, with greatest consensus for sarcoidosis cases and lowest for nonspecific interstitial lung disease cases. CONCLUSIONS A dedicated EQA for BAL fluid cellular analysis appears to be justified as the test material is substantially different from that of peripheral blood. We show that adequate analytical and post-analytical quality control can be achieved.
Collapse
Affiliation(s)
- A H Leontine Mulder
- Medlon B.V., Department of Clinical Chemistry and Laboratory Medicine, Enschede and Clinical Chemistry, Ziekenhuis Groep Twente, Almelo, The Netherlands
| | - Harrie H M Eidhof
- Medlon B.V., Department of Clinical Chemistry and Laboratory Medicine, Ziekenhuis Groep Twente, Enschede, The Netherlands
| | - Jan W Gratama
- Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
| |
Collapse
|